Table 2.
Human papillomavirus genotype-specific prevalences among invasive cervical cancer cases, meta-analytical estimates of relative oncogenic potentials
|
HPV- |
Prevalence* |
|
Cases†, n | Pooled OR | 95% CI | Studies‡, n | Cochran’s Q - test P | I2 statistic, % | Between-study variance |
|---|---|---|---|---|---|---|---|---|---|
| n | (%) | ||||||||
| 6 |
17 |
(0.8) |
2,208 |
0.08 |
0.04, 0.16 |
18 |
0.162 |
24.8 |
0.438 |
| 11 |
17 |
(1.1) |
1,554 |
0.11 |
0.06, 0.19 |
15 |
0.407 |
4.1 |
0.049 |
| 16 |
1,680 |
(57.9) |
2,902 |
|
Reference |
27 |
|
|
|
| 18 |
372 |
(12.8) |
2,902 |
0.63 |
0.51, 0.78 |
27 |
0.425 |
2.6 |
0.009 |
| 30 |
2 |
(0.5) |
430 |
0.13 |
0.03, 0.60 |
3 |
0.881 |
0.0 |
0.000 |
| 31 |
122 |
(4.4) |
2,745 |
0.22 |
0.14, 0.35 |
24 |
<0.001 |
55.9 |
0.696 |
| 33 |
128 |
(4.7) |
2,728 |
0.22 |
0.12, 0.38 |
24 |
<0.001 |
65.1 |
1.152 |
| 34 |
1 |
(0.2) |
666 |
0.21 |
0.06, 0.80 |
5 |
0.791 |
0.0 |
0.000 |
| 35 |
67 |
(2.7) |
2,450 |
0.12 |
0.08, 0.17 |
21 |
0.408 |
4.0 |
0.032 |
| 39 |
24 |
(1.2) |
2,017 |
0.17 |
0.09, 0.30 |
19 |
0.169 |
23.7 |
0.372 |
| 40 |
2 |
(0.2) |
991 |
0.13 |
0.04, 0.45 |
8 |
0.197 |
28.9 |
0.889 |
| 42 |
3 |
(0.2) |
1,573 |
0.05 |
0.02, 0.15 |
11 |
0.102 |
37.2 |
1.345 |
| 44 |
3 |
(0.4) |
729 |
0.14 |
0.03, 0.66 |
5 |
0.147 |
41.1 |
1.324 |
| 45 |
119 |
(4.8) |
2,464 |
0.35 |
0.22, 0.55 |
23 |
0.054 |
34.4 |
0.358 |
| 51 |
54 |
(2.7) |
1,971 |
0.10 |
0.05, 0.20 |
19 |
0.014 |
46.3 |
0.901 |
| 52 |
96 |
(4.0) |
2,394 |
0.16 |
0.11, 0.23 |
21 |
0.293 |
12.7 |
0.091 |
| 53 |
22 |
(1.1) |
1,981 |
0.07 |
0.04, 0.12 |
16 |
0.380 |
6.4 |
0.075 |
| 54 |
1 |
(0.1) |
1,263 |
0.06 |
0.02, 0.16 |
9 |
0.580 |
0.0 |
0.000 |
| 56 |
22 |
(1.0) |
2,303 |
0.09 |
0.05, 0.16 |
20 |
0.278 |
14.2 |
0.230 |
| 58 |
127 |
(4.7) |
2,685 |
0.24 |
0.15, 0.38 |
22 |
<0.001 |
56.8 |
0.583 |
| 59 |
24 |
(1.1) |
2,218 |
0.17 |
0.09, 0.31 |
16 |
0.537 |
0.0 |
0.000 |
| 61 |
2 |
(0.2) |
1,130 |
0.05 |
0.02, 0.14 |
8 |
0.739 |
0.0 |
0.000 |
| 62 |
1 |
(0.2) |
558 |
0.07 |
0.02, 0.23 |
6 |
0.420 |
0.0 |
0.000 |
| 66 |
16 |
(0.7) |
2,181 |
0.08 |
0.05, 0.14 |
18 |
0.799 |
0.0 |
0.000 |
| 67 |
4 |
(0.3) |
1,342 |
0.21 |
0.06, 0.67 |
10 |
0.181 |
28.6 |
1.020 |
| 68 |
8 |
(0.5) |
1,661 |
0.07 |
0.04, 0.14 |
14 |
0.439 |
0.8 |
0.013 |
| 69 |
9 |
(1.3) |
672 |
0.28 |
0.09, 0.92 |
5 |
0.249 |
25.8 |
0.473 |
| 70 |
6 |
(0.4) |
1,496 |
0.07 |
0.03, 0.14 |
11 |
0.565 |
0.0 |
0.000 |
| 71 |
1 |
(0.1) |
672 |
0.03 |
0.01, 0.13 |
4 |
0.527 |
0.0 |
0.000 |
| 73 |
8 |
(0.7) |
1,151 |
0.16 |
0.06, 0.41 |
10 |
0.617 |
0.0 |
0.000 |
| 74 |
1 |
(0.4) |
264 |
0.10 |
0.00, 3.41 |
2 |
0.051 |
73.8 |
4.874 |
| 81 |
1 |
(0.1) |
1,257 |
0.04 |
0.02, 0.10 |
11 |
0.966 |
0.0 |
0.000 |
| 82 | 4 | (0.4) | 892 | 0.13 | 0.04, 0.36 | 7 | 0.939 | 0.0 | 0.000 |
*HPV prevalence among cases, with no distinction between simple and multiple infections, across the studies that reported counts of the HPV genotypes under consideration. †Number of cases tested for the given HPV genotype. ‡Number of studies included in each meta-analysis. Abbreviations: HPV human papilloma virus, OR odds ratio, CI confidence interval.